

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 01 2000

In re application of: Soppet et al.

Application Serial No.: 09/236,468

Art Unit: 1643

Filed: January 25, 1999

JAN 27 2000

Examiner: S. Teng

For: **G-Protein Parathyroid Hormone
Receptor HLTDG74**

Attorney Docket No.: PF201D1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

S I R:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to the cited references listed on the attached form PTO 1449.

Copies of references C1-C9 were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 08/468,011, filed on June 6, 1995, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 08/468,011 for copies of references C1-C9.

Copies of references B1 and C10-C14 are appended hereto.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., deposit account no. 08-3425. A copy of this sheet is enclosed.

Date: January 27, 2000

Respectfully submitted,



Michelle S. Marks (Reg. No. 41,971)
Attorney for Applicant

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Phone (301) 610-5761

MSM/mbp